US009636412B2

(12) **United States Patent**
Bossard et al.

(10) **Patent No.: US 9,636,412 B2**
(45) **Date of Patent: May 2, 2017**

(54) **CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY**

(71) Applicant: **Nektar Therapeutics**, San Francisco, CA (US)

(72) Inventors: **Mary J. Bossard**, Madison, AL (US); **Gayle Stephenson-Phillips**, Harvest, AL (US)

(73) Assignee: **Nektar Therapeutics**, San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 83 days.

(21) Appl. No.: **14/819,212**

(22) Filed: **Aug. 5, 2015**

(65) **Prior Publication Data**

US 2016/0030587 A1 Feb. 4, 2016

Related U.S. Application Data

(63) Continuation of application No. 12/296,268, filed as application No. PCT/US2007/008738 on Apr. 6, 2007, now Pat. No. 9,101,670.

(60) Provisional application No. 60/790,339, filed on Apr. 7, 2009.

(51) **Int. Cl.**

C07K 16/24	(2006.01)
A61K 47/48	(2006.01)
A61K 39/44	(2006.01)
A61K 39/395	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 47/48215*** (2013.01); ***A61K 39/3955*** (2013.01); ***A61K 39/44*** (2013.01); ***C07K 16/241*** (2013.01); *C07K 2317/40* (2013.01); *C07K 2317/94* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,169,627	A	12/1992	Cunningham-Rundles
5,672,662	A	9/1997	Harris et al.
6,495,659	B2	12/2002	Bentley et al.
6,617,118	B2	9/2003	Roffler et al.
6,737,505	B2	5/2004	Bentley et al.
6,824,782	B2	11/2004	Whitlow et al.
6,992,168	B2	1/2006	Bentley et al.
7,012,135	B2	3/2006	Athwal et al.
7,138,371	B2	11/2006	DeFrees et al.
7,205,380	B2	4/2007	Bentley et al.
7,208,145	B2	4/2007	McManus et al.
7,402,662	B2	7/2008	Athwal et al.
7,416,858	B2	8/2008	DeFrees
7,446,174	B2	11/2008	Desjarlais et al.
2001/0026801	A1	10/2001	Tobinick
2004/0121415	A1	6/2004	King et al.
2004/0137557	A1	7/2004	DeFrees et al.
2005/0009988	A1	1/2005	Harris et al.
2005/0074425	A1	4/2005	Waugh et al.
2005/0180948	A1	8/2005	Desjarlais et al.
2005/0271663	A1	12/2005	Ignatovich et al.
2006/0073141	A1	4/2006	Ignatovich et al.
2006/0177892	A1	8/2006	DeFrees
2006/0257360	A1	11/2006	Desjarlais et al.
2006/0286066	A1*	12/2006	Basran A61K 47/48215 424/85.1
2007/0048219	A1*	3/2007	Hsei A61K 39/3955 424/1.49
2007/0269369	A1	11/2007	Gegg et al.
2010/0021481	A1	1/2010	Bossard et al.

FOREIGN PATENT DOCUMENTS

WO	WO 94/13322	6/1994
WO	WO 96/34015 A1	10/1996
WO	WO 98/25971	6/1998
WO	WO 01/94585	12/2001
WO	WO 03/099226	4/2003
WO	WO 03/080674	10/2003
WO	WO 2004/074345	9/2004
WO	WO 2004/081026	9/2004

OTHER PUBLICATIONS

Hurwitz et al., "Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies" (2000) vol. 49 pp. 226-234.*

Chapman, "PEGylated antibodies and antibody fragments for improved therapy: a review," Advanced Drug Delivery Reviews, 54, pp. 531-545, (2002).

Choy et al., "Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis : a phase II double-blinded, randomized, dose-escalating trial," Rheumatology, vol. 41, pp. 1133-1137, (2002).

Co, et al., "Genetically Engineered Deglycosylation of the Variable Domain Increases the Affinity of an Anti-CD33 Monoclonal Antibody," Molecular Immunology, vol. 30, No. 15, pp. 1361-1367, (1993).

Edwards et al., "Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases," Advanced Drug Delivery Reviews, vol. 55, pp. 1315-1336, (2003).

Furst et al., "A Phase 2 Dose-finding Study of PEGylated Recombinant Methionyl Human Soluble Tumor Necrosis Factor Type I in Patients with Rheumatoid Arthritis," J. Rheumatology, vol. 32, pp. 2303-2310, (2005).

Kamada et al., "Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice," Cancer Research, 60, pp. 6416-6420, (Nov. 15, 2000).

Kato, et al., "Activity enhancement of a lung cancer-associated human monoclonal antibody HB4C5 by N-deglycosylation," Hum. Antibod. Hybridomas, vol. 4, pp. 9-14, (1993).

(Continued)

Primary Examiner — Eric Olson

(74) *Attorney, Agent, or Firm* — Mark A. Wilson

(57) **ABSTRACT**

Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.

13 Claims, No Drawings